Promising Results In Medical Cannabis: CannaMore's Successful Phase 2a Trial For Colitis Treatment

Medical marijuana keeps showing positive results in treating various pathologies. CannaMore Biotechs, an Israel-based clinical-stage company, announced the successful completion of its Phase 2a clinical trial, which evaluated the safety and efficacy of a CBD-based enema formulation to treat patients with Ulcerative Colitis (UC).

What Happened?

The open-label, single-arm study, conducted over three months, involved ten patients. The goal was to assess the safety, tolerability and efficacy of IcBD-01, which is a CBD-based treatment for ulcerative colitis. The results were promising, with significant improvements in disease severity and patient-reported symptoms.

Why It Matters

The study achieved its primary endpoint, showing a reduction in Mayo scores, indicating a decrease in disease severity. Most participants reported substantial improvements in symptoms like reduced abdominal pain and better overall well-being. The formulation was well-tolerated, with no significant side effects, confirming its safety profile.

Prof. Timna Naftali, a specialist in gastroenterology at Meir Hospital in Kfar Saba, led the study. “The results of this trial are highly encouraging and support the potential of IcBD-01 as an effective treatment for Ulcerative Colitis,” said Naftali. “We observed significant improvements in both clinical outcomes and patient-reported symptoms.”

Read Also: New Study Shows High Use Of Medical Cannabis For Chronic Pain And Arthritis In Older Patients

Medical Cannabis Advancements

If future trials continue to yield positive results, UC could be added to the growing list of conditions treated with medical cannabis. At the moment, cannabis is used to treat various conditions, including chronic pain, multiple sclerosis, epilepsy, anxiety, depression, PTSD, and neuropathic pain. Cannabis’ efficacy in managing chemotherapy-induced nausea and vomiting, as well as muscle spasms from neurological conditions, has been well-documented​.

CannaMore Biotechs plans to advance to the next stage of clinical trials to further evaluate the long-term efficacy and safety of IcBD-01 while exploring immediate market opportunities in medical cannabis.

• Read Next: Study Affirms Cannabis Helps Reduce Neuropathic Pain Intensity From Spinal Cord Injury By 30%

Cover Image: Generated via Dall-E